Breast Cancer
Conditions
Brief summary
This is a multicenter, retrospective real-world study aiming to evaluate the efficacy and safety of post-antibody-drug conjugate (post-ADC) treatment strategies in patients with HER2-low advanced breast cancer who have developed resistance to prior ADC therapy. The study plans to enroll approximately 220 eligible patients from three centers in China (Jiangsu Province Hospital, Nanjing Drum Tower Hospital, and Nanjing General Hospital of Nanjing Military Command) between January 2018 and December 2025. Key efficacy outcomes include progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR). Safety outcomes include the incidence of grade 3/4 adverse events and serious adverse events. Subgroup analyses will compare different post-ADC regimens (e.g., alternative ADC, chemotherapy, endocrine therapy, immunotherapy) and explore the impact of visceral metastasis and prior ADC treatment response on subsequent outcomes. This study seeks to identify optimal post-ADC treatment strategies and preferred patient populations for clinical benefit.
Interventions
None listed
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* females aged ≥18 years. * confirmed pathologic diagnosis of HER2-low MBC (defined as HER2 IHC 1+ or 2+ without gene amplification by FISH detection). * patients had disease progression following ADC treatment in advanced setting and had undergone at least one available efficacy evaluation. * patients received at least one subsequent anti-tumor treatment following ADC failure, with at least one available efficacy evaluation.
Exclusion criteria
* patients previously treated with ADC during neoadjuvant or adjuvant setting. * patients who had not experienced disease progression on their first ADC (ADC1) regimen and remained on ADC1 treatment. * patients with no documented subsequent anti-tumor therapy following ADC1 treatment. * patients who lacked evaluable efficacy assessment data during ADC1 or post-ADC therapy. * patients with incomplete clinicopathological information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| real-world (rwPFS) of post-ADC therapy | up to 12 months. | the duration from the post-ADC treatment initiation to either disease progression or death from any cause, whichever came first |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| objective response rate (ORR) | at 12 weeks | ORR was defined as the percentage of patients achieving a best overall response of complete response (CR) or partial response (PR). |
| Clinical benefit rate (CBR) of post-ADC therapy | at 12 weeks | CBR was determined by the percentage of patients achieving disease control, defined as complete response (CR), partial response (PR), or stable disease (SD). |
| overall survival (OS) of post-ADC therapy | up to 24 months | Overall survival was defined as the duration from post-ADC treatment initiation to death from any cause. |
Countries
China
Outcome results
None listed